CIMZIA (also known as Certolizumab pegol)
Cimzia is a fragment of an antibody that binds and inhibits tumor necrosis factor alpha (TNFα).
Because TNFα is core chemical messenger in inflammation, Cimzia has been found to be effective in treating many autoimmune conditions.
- Active, moderate-to-severe Crohn’s disease
- Active, moderate-to-severe Rheumatoid Arthritis
- Active, psoriatic arthritis
- Active ankylosing spondylitis
Cimzia should not be started during an active infection. Patients with heart failure and hepatitis B should consult their physicians prior to starting on Cimzia.
Cimzia is administered by subcutaneous injection in thigh or abdomen. Patients typically receive the subcutaneous injection every 2 weeks for the first 3 doses and every 4 weeks thereafter.